{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T15:48:37Z","timestamp":1792856917259,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007700","name":"Universitatea de Medicin\u0103 \u015fi Farmacie \"Carol Davila\" Bucure\u015fti","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Antimicrobial resistance amongst\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      isolates imposes a significant clinical and public health burden, requiring a large healthcare expense for the treatment of infections. The last decade has seen an incremental rise in antimicrobial resistance, not only toward carbapenems, but also last-resort antimicrobials, urging the need for collaboration between infectious diseases specialists and microbiology peers toward the development of novel therapeutic methods. This study aims to provide a two-year overview in carbapenem-resistant\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      (CRKP) in an infectious diseases tertiary hospital in Romania, focusing on antimicrobial resistance patterns and carbapenemase distribution.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Clinical samples collected from patients admitted to the \u201cProf. Dr. Matei Bals\u201d National Institute of Infectious Diseases in Bucharest, Romania, between 1st August 2023 and 31st July 2025 have undergone standard cultivation, bacterial identification and antimicrobial susceptibility testing according to standard laboratory protocol. All carbapenem-non-susceptible\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      strains (meropenem minimum inhibitory concentration &amp;gt; 0.125 \u03bcg\/mL) further underwent extended-spectrum beta-lactamase (ESBL) and carbapenemase production testing via phenotypical methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A number of 340 non-duplicate, carbapenem-non-susceptible\n                      <jats:italic>Klebsiella pneumoniae<\/jats:italic>\n                      strains have been isolated from various clinical samples. The majority of them (&amp;gt; 90%) exhibited carbapenemase production:\n                      <jats:italic>n<\/jats:italic>\n                      = 164, 53.59% double NDM and OXA-48-type carbapenemase producers, followed by NDM (\n                      <jats:italic>n<\/jats:italic>\n                      = 74, 24.18%), OXA-48-type (\n                      <jats:italic>n<\/jats:italic>\n                      = 44, 14.38%), KPC (\n                      <jats:italic>n<\/jats:italic>\n                      = 14, 5.56%) and NDM+KPC (\n                      <jats:italic>n<\/jats:italic>\n                      = 7, 2.29%). In addition, 309 strains were deemed ESBL producers. In terms of antimicrobial resistance, more than &amp;gt; 90% of the strains exhibited resistance to fluoroquinolones, third generation cephalosporins, penicillins and monobactams, &amp;gt; 75% resistance to aminoglycosides and novel beta-lactam\/beta-lactamase inhibitor combinations and &amp;gt; 70% resistance to colistin and imipenem-relebactam. Overall cefiderocol resistance was 32.05%. Upon classification, 25.00% (\n                      <jats:italic>n<\/jats:italic>\n                      = 85) of isolates were multidrug-resistant (MDR), 56.47% (\n                      <jats:italic>n<\/jats:italic>\n                      = 192) extensively drug-resistant (XDR) and 17.06% (\n                      <jats:italic>n<\/jats:italic>\n                      = 58) were pandrug-resistant (PDR). Moreover, 54.17% (\n                      <jats:italic>n<\/jats:italic>\n                      = 104) of XDR isolates were only susceptible to one antimicrobial drug.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Rates of resistance remain concerningly high amongst CRKP isolates, with double carbapenemase producers and XDR\/PDR isolates dominating the landscape, implying the foreseeable need for updated means of approaching antimicrobial resistance, as last-resort antimicrobials become less effective through increasing resistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmicb.2025.1728843","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:37Z","timestamp":1767854197000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Insights into Klebsiella pneumoniae carbapenem resistance\u2014a two-year retrospective study from a Romanian tertiary care hospital"],"prefix":"10.3389","volume":"16","author":[{"given":"Daniela","family":"T\u0103l\u0103pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihai-Octavian","family":"Dan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Cire\u015f\u0103","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandru","family":"Rafila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.3390\/ijms22084042","article-title":"Prophylaxis and treatment against Klebsiella pneumoniae: Current insights on this emerging anti-microbial resistant global threat.","volume":"22","author":"Arato","year":"2021","journal-title":"IJMS"},{"key":"B2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/14787210.2023.2184346","article-title":"Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: Is it superior to polymyxin monotherapy?","volume":"21","author":"Ardebili","year":"2023","journal-title":"Exp. Rev. Anti-infective Therapy"},{"key":"B3","doi-asserted-by":"crossref","DOI":"10.5772\/intechopen.90100","article-title":"Carbapenem resistance: Mechanisms and drivers of global menace","volume-title":"Pathogenic bacteria","author":"Aslam","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"421","DOI":"10.3390\/antibiotics11030421","article-title":"Mechanisms of action of carbapenem resistance.","volume":"11","author":"Aurilio","year":"2022","journal-title":"Antibiotics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s40121-024-01097-9","article-title":"Carbapenemase-Producing enterobacterales from patients arriving from Ukraine in Poland, March 2022-February 2023.","volume":"14","author":"Biedrzycka","year":"2025","journal-title":"Infect. Dis. Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.18683\/germs.2025.1468","article-title":"One-year surveillance of last-resort antimicrobial resistance patterns in carbapenemase-producing Klebsiella pneumoniae strains isolated in a Romanian tertiary care hospital: A prospective study.","volume":"15","author":"Dan","year":"2025","journal-title":"Germs"},{"key":"B7","doi-asserted-by":"publisher","first-page":"FSO438","DOI":"10.2144\/fsoa-2019-0098","article-title":"A review on bacterial resistance to carbapenems: Epidemiology, detection and treatment options.","volume":"6","author":"Elshamy","year":"2020","journal-title":"Future Sci. OA"},{"key":"B8","volume-title":"Surveillance atlas of infectious diseases.","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1093\/jac\/dkac221","article-title":"Evolution of \u03b2-lactamase-mediated cefiderocol resistance.","volume":"77","author":"Fr\u00f6hlich","year":"2022","journal-title":"J. Antimicrob. Chemotherapy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3390\/antibiotics12020234","article-title":"Carbapenem-Resistant Klebsiella pneumoniae: Virulence factors, molecular epidemiology and latest updates in treatment options.","volume":"12","author":"Karampatakis","year":"2023","journal-title":"Antibiotics"},{"key":"B11","doi-asserted-by":"publisher","first-page":"106646","DOI":"10.1016\/j.ijantimicag.2022.106646","article-title":"Catecholate siderophore receptor CirA impacts cefiderocol susceptibility in Klebsiella pneumoniae.","volume":"60","author":"Lan","year":"2022","journal-title":"Intern. J. Antimicrob. Agents"},{"key":"B12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.3390\/antibiotics13050435","article-title":"Carbapenem-Resistant NDM and OXA-48-like producing K. pneumoniae: From menacing superbug to a mundane bacteria; a retrospective study in a romanian tertiary hospital.","volume":"13","author":"Lazar","year":"2024","journal-title":"Antibiotics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance.","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e01779-21","DOI":"10.1128\/Spectrum.01779-21","article-title":"In vitro evolution of cefiderocol resistance in an NDM-Producing Klebsiella pneumoniae due to functional loss of CirA.","volume":"9","author":"McElheny","year":"2021","journal-title":"Microbiol. Spectr."},{"key":"B15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.3390\/antibiotics14080783","article-title":"Epidemiology of carbapenem-resistant klebsiella pneumoniae co-producing mbl and oxa-48-like in a romanian tertiary hospital: A call to action.","volume":"14","author":"Melinte","year":"2025","journal-title":"Antibiotics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2200850","DOI":"10.2807\/1560-7917.ES.2023.28.1.2200850","article-title":"Molecular surveillance of multidrug-resistant Gram-negative bacteria in Ukrainian patients, Germany, March to June 2022.","volume":"28","author":"Schultze","year":"2023","journal-title":"Euro Surveill."},{"key":"B17","doi-asserted-by":"publisher","first-page":"703","DOI":"10.3390\/antibiotics14070703","article-title":"Mechanisms of cefiderocol resistance in carbapenemase-producing enterobacterales: Insights from comparative genomics.","volume":"14","author":"Tristancho-Bar\u00f3","year":"2025","journal-title":"Antibiotics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2300571","DOI":"10.2807\/1560-7917.ES.2023.28.47.2300571","article-title":"Emergence and persistent spread of carbapenemase-producing Klebsiella pneumoniae high-risk clones in Greek hospitals, 2013 to 2022.","volume":"28","author":"Tryfinopoulou","year":"2023","journal-title":"Eurosurveillance"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/microorganisms13092132","article-title":"Epidemiological and microbiological characterization of carbapenemase-producing Klebsiella pneumoniae isolates in a regional greek hospital: A retrospective study.","volume":"13","author":"Tsolakidou","year":"2025","journal-title":"Microorganisms"},{"key":"B20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and ceftolozane\/tazobactam: Second-generation \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations.","volume":"63","author":"Van Duin","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41467-023-44351-3","article-title":"Increase in antioxidant capacity associated with the successful subclone of hypervirulent carbapenem-resistant Klebsiella pneumoniae ST11-KL64.","volume":"15","author":"Wang","year":"2024","journal-title":"Nat. Commun."},{"key":"B22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12941-017-0191-3","article-title":"Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae.","volume":"16","author":"Xu","year":"2017","journal-title":"Ann. Clin. Microbiol. Antimicrob."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e1019","DOI":"10.1128\/aac.01019-24","article-title":"Effects of different carbapenemase and siderophore production on cefiderocol susceptibility in Klebsiella pneumoniae.","volume":"68","author":"Yang","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"B24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12866-023-02974-y","article-title":"Exploring multidrug-resistant Klebsiella pneumoniae antimicrobial resistance mechanisms through whole genome sequencing analysis.","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Microbiol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2200896","DOI":"10.2807\/1560-7917.ES.2022.27.50.2200896","article-title":"Multidrug-resistant organisms in patients from Ukraine in the Netherlands, March to August 2022.","volume":"27","author":"Zwittink","year":"2022","journal-title":"Euro Surveill."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1728843\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T06:36:38Z","timestamp":1767854198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1728843\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":25,"alternative-id":["10.3389\/fmicb.2025.1728843"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1728843","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1728843"}}